Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...
To make life easier for people with a common bladder condition, Medtronic is digging in far away from urinary tract. Treatment for urinary urge incontinence can require pads, absorbent underwear and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback